Toward a more patient‐centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS)

Abstract Notable treatment advances have been made in recent years for patients with myelodysplastic syndromes/neoplasms (MDS), and several new drugs are under development. For example, the emerging availability of oral MDS therapies holds the promise of improving patients' health‐related quality of...

Descripció completa

Dades bibliogràfiques

Autors principals:	Fabio Efficace, Rena Buckstein, Gregory A. Abel, Johannes M. Giesinger, Pierre Fenaux, Jan Philipp Bewersdorf, Andrew M. Brunner, Rafael Bejar, Uma Borate, Amy E. DeZern, Peter Greenberg, Gail J. Roboz, Michael R. Savona, Francesco Sparano, Jacqueline Boultwood, Rami Komrokji, David A. Sallman, Zhuoer Xie, Guillermo Sanz, Hetty E. Carraway, Justin Taylor, Stephen D. Nimer, Matteo Giovanni Della Porta, Valeria Santini, Maximilian Stahl, Uwe Platzbecker, Mikkael A. Sekeres, Amer M. Zeidan
Format:	Artigo
Idioma:	Inglês
Publicat:	Wiley 2024-05-01
Col·lecció:	HemaSphere
Accés en línia:	https://doi.org/10.1002/hem3.69
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!